Investment
Features
FeesSafety
Academy
More
Pluang+

Cross Timbers Royalty Trust declares $0.0643/unit cash distribution for Oct 15 payment.

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Neutral
Cross Timbers Royalty Trust declares $0.0643/unit cash distribution for Oct 15 payment.

Cross Timbers Royalty Trust announced a cash distribution of $0.064277 per unit payable on October 15, 2026, to unitholders of record as of September 30, 2026. The distribution reflects underlying oil and gas sales with oil prices around $76.19 per barrel and gas prices at $4.67 per Mcf for the current month. The Trust also reported changes in excess costs related to Texas and Oklahoma properties, with cumulative excess costs totaling over $6.3 million for Texas and $488,000 for Oklahoma. Investors can find more details and historical data on the Trust's website.

Cross Timbers Royalty Trust declared a cash distribution of $0.064277 per unit payable in October 2026. For readers following the Energy sector, here is Pluang's market snapshot as of Sep 18, 2026 19:11 WIB: out of 34 priced US Energy stocks, 4 rose and 27 fell. Notable prices include Suncor Energy Inc. at USD 69.01 with a 1-day change of -0.69%, Baker Hughes Co at USD 56.19 with -0.66%, and Chevron Corp at USD 210.23 with -0.64%. Typical hold times on Pluang range from 56 to 100 days, with strong buy order activity for these names.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox's board approved a quarterly cash dividend of $1.36 per share, payable on October 15, 2026, to shareholders recorded by September 30, 2026. This dividend reflects Lennox's ongoing commitment to returning value to its investors. Lennox is a lea...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App